vs

Side-by-side financial comparison of SONOCO PRODUCTS CO (SON) and Steris (STE). Click either name above to swap in a different company.

SONOCO PRODUCTS CO is the larger business by last-quarter revenue ($1.7B vs $1.5B, roughly 1.1× Steris). Steris runs the higher net margin — 12.9% vs 4.1%, a 8.8% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs -1.9%). Steris produced more free cash flow last quarter ($199.5M vs $-428.3B). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 1.2%).

Sonoco Products Company is an American provider of diversified consumer packaging, industrial products, protective packaging, and packaging supply chain services and the world's largest producer of composite cans, tubes, and cores. The company was founded in 1889 as Southern Novelty Company with annualized net sales of approximately $7.3 billion. Sonoco has 19,900 employees in more than 335 operations in 33 countries, serving more than 85 nations. The company is headquartered in Hartsville, S...

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

SON vs STE — Head-to-Head

Bigger by revenue
SON
SON
1.1× larger
SON
$1.7B
$1.5B
STE
Growing faster (revenue YoY)
STE
STE
+11.1% gap
STE
9.2%
-1.9%
SON
Higher net margin
STE
STE
8.8% more per $
STE
12.9%
4.1%
SON
More free cash flow
STE
STE
$428.5B more FCF
STE
$199.5M
$-428.3B
SON
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
1.2%
SON

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
SON
SON
STE
STE
Revenue
$1.7B
$1.5B
Net Profit
$68.0M
$192.9M
Gross Margin
20.6%
43.8%
Operating Margin
7.6%
18.3%
Net Margin
4.1%
12.9%
Revenue YoY
-1.9%
9.2%
Net Profit YoY
25.9%
11.2%
EPS (diluted)
$0.68
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SON
SON
STE
STE
Q1 26
$1.7B
Q4 25
$1.8B
$1.5B
Q3 25
$2.1B
$1.5B
Q2 25
$1.9B
$1.4B
Q1 25
$1.7B
$1.5B
Q4 24
$1.4B
Q3 24
$1.7B
$1.3B
Q2 24
$1.6B
$1.3B
Net Profit
SON
SON
STE
STE
Q1 26
$68.0M
Q4 25
$332.2M
$192.9M
Q3 25
$122.9M
$191.9M
Q2 25
$493.4M
$177.4M
Q1 25
$54.4M
$145.7M
Q4 24
$173.5M
Q3 24
$50.9M
$150.0M
Q2 24
$90.8M
$145.4M
Gross Margin
SON
SON
STE
STE
Q1 26
20.6%
Q4 25
19.6%
43.8%
Q3 25
21.9%
44.2%
Q2 25
21.3%
45.1%
Q1 25
20.7%
43.3%
Q4 24
44.5%
Q3 24
21.4%
43.6%
Q2 24
22.0%
44.7%
Operating Margin
SON
SON
STE
STE
Q1 26
7.6%
Q4 25
29.4%
18.3%
Q3 25
9.1%
18.2%
Q2 25
9.2%
17.7%
Q1 25
7.4%
14.6%
Q4 24
17.9%
Q3 24
7.6%
16.5%
Q2 24
8.6%
14.5%
Net Margin
SON
SON
STE
STE
Q1 26
4.1%
Q4 25
18.8%
12.9%
Q3 25
5.8%
13.1%
Q2 25
25.8%
12.8%
Q1 25
3.2%
9.8%
Q4 24
12.7%
Q3 24
3.0%
11.3%
Q2 24
5.6%
11.4%
EPS (diluted)
SON
SON
STE
STE
Q1 26
$0.68
Q4 25
$3.33
$1.96
Q3 25
$1.23
$1.94
Q2 25
$4.96
$1.79
Q1 25
$0.55
$1.48
Q4 24
$1.75
Q3 24
$0.51
$1.51
Q2 24
$0.92
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SON
SON
STE
STE
Cash + ST InvestmentsLiquidity on hand
$224.5M
$423.7M
Total DebtLower is stronger
$3.5B
$1.9B
Stockholders' EquityBook value
$3.6B
$7.2B
Total Assets
$11.1B
$10.6B
Debt / EquityLower = less leverage
0.97×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SON
SON
STE
STE
Q1 26
$224.5M
Q4 25
$378.4M
$423.7M
Q3 25
$244.9M
$319.2M
Q2 25
$329.8M
$279.7M
Q1 25
$181.8M
$171.7M
Q4 24
$155.2M
Q3 24
$1.9B
$172.2M
Q2 24
$140.2M
$198.3M
Total Debt
SON
SON
STE
STE
Q1 26
$3.5B
Q4 25
$3.8B
$1.9B
Q3 25
$3.8B
$1.9B
Q2 25
$5.0B
$1.9B
Q1 25
$5.0B
$1.9B
Q4 24
$2.0B
Q3 24
$4.3B
$2.2B
Q2 24
$2.5B
$2.2B
Stockholders' Equity
SON
SON
STE
STE
Q1 26
$3.6B
Q4 25
$3.6B
$7.2B
Q3 25
$3.3B
$7.0B
Q2 25
$3.2B
$7.0B
Q1 25
$2.4B
$6.6B
Q4 24
$6.4B
Q3 24
$2.5B
$6.6B
Q2 24
$2.4B
$6.4B
Total Assets
SON
SON
STE
STE
Q1 26
$11.1B
Q4 25
$11.2B
$10.6B
Q3 25
$11.7B
$10.4B
Q2 25
$12.0B
$10.4B
Q1 25
$12.7B
$10.1B
Q4 24
$10.0B
Q3 24
$9.0B
$10.2B
Q2 24
$7.2B
$10.1B
Debt / Equity
SON
SON
STE
STE
Q1 26
0.97×
Q4 25
1.05×
0.27×
Q3 25
1.15×
0.27×
Q2 25
1.54×
0.27×
Q1 25
2.03×
0.29×
Q4 24
0.32×
Q3 24
1.74×
0.33×
Q2 24
1.04×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SON
SON
STE
STE
Operating Cash FlowLast quarter
$298.2M
Free Cash FlowOCF − Capex
$-428.3B
$199.5M
FCF MarginFCF / Revenue
-25547.4%
13.3%
Capex IntensityCapex / Revenue
3600.5%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$-427.6B
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SON
SON
STE
STE
Q1 26
Q4 25
$412.9M
$298.2M
Q3 25
$291.5M
$287.8M
Q2 25
$193.4M
$420.0M
Q1 25
$-208.1M
$260.8M
Q4 24
$332.8M
Q3 24
$162.1M
$250.7M
Q2 24
$109.3M
$303.7M
Free Cash Flow
SON
SON
STE
STE
Q1 26
$-428.3B
Q4 25
$322.3M
$199.5M
Q3 25
$225.6M
$201.3M
Q2 25
$98.6M
$326.4M
Q1 25
$-300.8M
$189.9M
Q4 24
$243.6M
Q3 24
$70.5M
$148.8M
Q2 24
$16.0M
$195.7M
FCF Margin
SON
SON
STE
STE
Q1 26
-25547.4%
Q4 25
18.2%
13.3%
Q3 25
10.6%
13.8%
Q2 25
5.2%
23.5%
Q1 25
-17.6%
12.8%
Q4 24
17.8%
Q3 24
4.2%
11.2%
Q2 24
1.0%
15.3%
Capex Intensity
SON
SON
STE
STE
Q1 26
3600.5%
Q4 25
5.1%
6.6%
Q3 25
3.1%
5.9%
Q2 25
5.0%
6.7%
Q1 25
5.4%
4.8%
Q4 24
6.5%
Q3 24
5.5%
7.7%
Q2 24
5.7%
8.4%
Cash Conversion
SON
SON
STE
STE
Q1 26
Q4 25
1.24×
1.55×
Q3 25
2.37×
1.50×
Q2 25
0.39×
2.37×
Q1 25
-3.82×
1.79×
Q4 24
1.92×
Q3 24
3.18×
1.67×
Q2 24
1.20×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SON
SON

Consumer Packaging$1.1B65%
Industrial Paper Packaging$587.5M35%
All Other$55.1M3%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons